Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 22, 2017 16:42 ET | Source: Novartis Pharma AG

Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label

Inclusion of Treatment-free Remission (TFR) data provides additional and novel option in management of Ph+ CML-CP Deep and sustained molecular response included as key eligibility criteria for...
December 22, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma

Priority Review designation based on Phase III study showing 53% reduction in risk of recurrence or death with Tafinlar + Mekinist, as compared to placebo[1] Improvements observed in key...
December 15, 2017 01:00 ET | Source: Novartis Pharma AG

Novartis announces Oncology head to retire

Basel, December 15, 2017 - Novartis announced today that Bruno Strigini, CEO Novartis Oncology has decided to retire from Novartis and the industry for personal reasons. Joseph Jimenez, CEO of...
December 15, 2017 01:00 ET | Source: Novartis Pharma AG

Novartis gibt Rücktritt des Onkologie-Chefs bekannt

Basel, 15. Dezember 2017 - Novartis gibt bekannt, dass sich Bruno Strigini, CEO Novartis Onkologie, entschieden hat, die Firma aus persönlichen Gründen zu verlassen und sich aus der Industrie...
December 11, 2017 10:49 ET | Source: Novartis Pharma AG

Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study

Investigational therapy crizanlizumab (SEG101, formerly SelG1) approximately doubled the time to first on-treatment sickle cell pain crisis, according to new subgroup analysis of Phase II SUSTAIN...
December 10, 2017 10:37 ET | Source: Novartis Pharma AG

Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer

At six months, 30% of patients treated with Kymriah were in complete response, with a 74% relapse-free rate after onset of response; median duration of response was not reached Grade 3/4...
December 08, 2017 01:15 ET | Source: Novartis Pharma AG

Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine

Phase I study demonstrates matching pharmacokinetic (PK), pharmacodynamic (PD), safety and immunogenicity profiles of Sandoz biosimilar pegfilgrastim and reference medicine Pegfilgrastim is a...
December 07, 2017 01:00 ET | Source: Novartis Pharma AG

Novartis tender offer for Advanced Accelerator Applications commences

Basel, December 7, 2017 -Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S.A., a société anonyme organized under the laws of...
December 06, 2017 13:15 ET | Source: Novartis Pharma AG

Kisqali® first and only CDK4/6 inhibitor to show superior efficacy vs. oral endocrine therapy as 1L treatment in randomized Phase III trial in premenopausal women with HR+/HER2- advanced breast cancer

Kisqali plus an oral endocrine partner demonstrated significant efficacy with sustained benefit of nearly two years (median PFS 23.8 vs 13.0 months for endocrine therapy...
November 30, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis' Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients

Unique Cosentyx® (secukinumab) data reinforce treatment option for up to 90% of psoriasis patients who may develop nail or palmoplantar psoriasis[1]-[4] Cosentyx results represent the first data...